Rubivirus Vaccine

Creative Biolabs relies on a professional vaccine research platform. After more than ten years of development, it has established a mature and comprehensive multi-type vaccine development and service system. The company has a professional R & D team and has in-depth research in the field of rubella vaccine research and development. We have the ability to design and prepare various types of safe rubella vaccines with good immunogenicity and can provide various services including optimization of efficacy and vaccine evaluation and so on.

Rubella and Rubella Virus

Symptom of rubella is often mild and nearly 50% people even do not realize the infection. The disease is also known as three-day measles or German measles. Generally, people who got the infection may have rashes on their faces at first, which would then distribute to the rest of the bodies. These rashes are itchy in some people and are different from that caused by measles as they are less bright. One common phenomenon of the disease is swollen lymph nodes and the situation would last for several weeks. Notably, infection in early pregnancy can cause miscarriage or cause congenital rubella syndrome (CRS) in newborns. Symptoms of CRS include cataracts, hearing impairments, and heart as well as brain damage, which rarely occur after 20 weeks of pregnancy. The infected population spreads rubella in the air by coughing, and human beings are the only susceptible group.

The causative agent of rubella is rubella virus, which is the only member of the Rubivirus genus in the Togaviridae family. Genome of the virus is a single-stranded and positive-sense RNA. Contact with respiratory fluid could transmit the virus and rubella virus infects respiratory tract at first and then replicates there.

Capsid protein is a virulence factor of the rubella virus because it can assist virus replicate in the host cells and help the virus escape from immune response of the host. The capsid protein of the virus is multi-functional such as acting as structural or non-structural proteins as well as functioning as replication complex. IgM, IgG, and IgA play an important role in the defense of rubella virus. T cell-mediated cellular immune response is also of significance in the part of anti-virus. In addition, activation of cytotoxic T cells is another key point in combating the infection. Intensity of the response of rubella-specific memory B cells stimulated by vaccines may be a correlation to the protective immunity.

The Development of Rubella Vaccine

The live rubella virus vaccine currently approved for marketing in the United States is RA27/3 strain, which was isolated from an infected fetus in the 1960s and serially passaged to achieve attenuation. It is currently being used as a part of the measles-mumps-rubella (MMR) combination vaccine to exert the function of prevention of rubella. RA27/3 is of high immunogenicity in eliciting strong cellular and humoral immune responses and anti-rubella antibodies it induced are life-long. The vaccine generally needs to be vaccinated twice, the first time at 12 months of age and the second at 5 years of age. RA27/3 is especially recommended for vaccination in women of childbearing age. Pregnant women should not be vaccinated to avoid virus infecting the fetus and cause CRS.

Creative Biolabs is an innovative vaccine development and service-providing company. In the more than ten years of growth, the company has provided high-quality vaccine products and services to customers around the world. We have a world-class R&D team with mature platforms and technologies to meet all your needs in vaccine research and production.

All of our products can only be used for research purposes. These vaccine ingredients CANNOT be used directly on humans or animals.